Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Comparison of three adjuvant chemotherapy regimes using an extended log-logistic model in women with operable breast cancer.

Faradmal J, Kazemnejad A, Khodabakhshi R, Gohari MR, Hajizadeh E.

Asian Pac J Cancer Prev. 2010;11(2):353-8.

2.

Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens.

Wang S, Shi Y, Yuan Z, Wang X, Liu D, Peng R, Teng X, Qin T, Peng J, Lin G, Jiang X.

Med Oncol. 2012 Jun;29(2):547-53. doi: 10.1007/s12032-011-9964-2. Epub 2011 Apr 29.

PMID:
21528408
3.

Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea.

Najafi S, Djavid GE, Mehrdad N, Rajaii E, Alavi N, Olfatbakhsh A, Najafi M, Bahrami A, Heidari K.

Menopause. 2011 Feb;18(2):208-12. doi: 10.1097/gme.0b013e3181f3e6e7.

PMID:
21037487
4.

Taxane-based regimens as adjuvant treatment for breast cancer: a retrospective study in egyptian cancer patients.

Azim HA, Abdal-Kader YS, Mousa MM, Malek RA, Abdalmassih MK, Ibrahim NY.

Asian Pac J Cancer Prev. 2015;16(1):65-9.

5.
6.

Adjuvant chemotherapy in early breast cancer.

Ejlertsen B.

Dan Med J. 2016 May;63(5). pii: B5222. Review.

PMID:
27127018
7.

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.

Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, Nordenskjöld B, Lang I, Jakesz R, Vorobiof D, Gutiérrez J, van Hazel G, Dolci S, Jamin S, Bendahmane B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Piccart-Gebhart M; BIG 02-98 Collaborative Group.

J Natl Cancer Inst. 2008 Jan 16;100(2):121-33. doi: 10.1093/jnci/djm287. Epub 2008 Jan 8. Erratum in: J Natl Cancer Inst. 2008 Nov 19;100(22):1655.

PMID:
18182617
8.

A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.

Kuru B, Camlibel M, Dinc S, Gulcelik MA, Atalay C, Alagol H.

J Exp Clin Cancer Res. 2005 Sep;24(3):363-72.

PMID:
16270522
9.

Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience.

Leone JP, Leone J, Vallejo CT, Pérez JE, Romero AO, Machiavelli MR, Romero Acuña L, Domínguez ME, Langui M, Fasce HM, Leone BA, Ortiz E, Iturbe J, Zwenger AO.

Breast Cancer Res Treat. 2014 Jan;143(2):313-23. doi: 10.1007/s10549-013-2806-5. Epub 2013 Dec 11.

PMID:
24327333
10.

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.

Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, Camps C, Carrato A, Casado A, Candel MT, Albanell J, Aranda J, Munarriz B, Campbell J, Diaz-Rubio E; GEICAM Group (Spanish Breast Cancer Research Group), Spain.

Ann Oncol. 2003 Jun;14(6):833-42. Review.

PMID:
12796019
11.

pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials.

Reinisch M, Huober J, von Minckwitz G, Blohmer JU, Denkert C, Hanusch C, Jackisch C, Kümmel S, Schneeweiss A, Rhiem K, Lederer B, Untch M, Nekljudova V V, Loibl S.

Breast. 2017 Apr;32:73-78. doi: 10.1016/j.breast.2016.12.020. Epub 2017 Jan 5.

PMID:
28063331
12.

3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.

Ferreira Filho AF, Crown J, Cardoso F, Nogaret JM, Duffy K, Dolci S, Rowan S, O'Higgins N, Batter V, Paesmans M, Piccart MJ, Di Leo A.

Anticancer Res. 2002 Jul-Aug;22(4):2471-6.

PMID:
12174946
13.
14.
16.

Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

Misset JL, di Palma M, Delgado M, Plagne R, Chollet P, Fumoleau P, Le Mevel B, Belpomme D, Guerrin J, Fargeot P, Metz R, Ithzaki M, Hill C, Mathé G.

J Clin Oncol. 1996 Apr;14(4):1136-45.

PMID:
8648368
17.

Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.

Ploner F, Jakesz R, Hausmaninger H, Kolb R, Stierer M, Fridrik M, Steindorfer P, Gnant M, Haider K, Mlineritsch B, Tschurtschenthaler G, Steger G, Seifert M, Kubista E, Samonigg H; Austrian Breast And Colorectal Cancer Study Group.

Onkologie. 2003 Apr;26(2):115-9.

PMID:
12771518
18.

Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.

Gilabert M, Bertucci F, Esterni B, Madroszyk A, Tarpin C, Jacquemier J, Extra JM, Viens P, Gonçalves A.

Anticancer Res. 2011 Mar;31(3):1079-86.

PMID:
21498742
20.

Supplemental Content

Support Center